Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
2.450
-0.100 (-3.92%)
Nov 4, 2024, 4:00 PM EST - Market closed

Moleculin Biotech Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2015
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2015
Selling, General & Admin
9.3510.0211.548.396.796.31
Upgrade
Research & Development
18.2519.4918.9714.4212.7611.01
Upgrade
Operating Expenses
27.7329.6330.6422.9719.7417.52
Upgrade
Operating Income
-27.73-29.63-30.64-22.97-19.74-17.52
Upgrade
Interest & Investment Income
0.991.370.240.310.010.01
Upgrade
Other Non Operating Income (Expenses)
1.58-1.511.386.772.374.08
Upgrade
EBT Excluding Unusual Items
-25.17-29.77-29.03-15.89-17.36-13.43
Upgrade
Pretax Income
-25.17-29.77-29.03-15.89-17.36-13.43
Upgrade
Income Tax Expense
------0.23
Upgrade
Net Income
-25.17-29.77-29.03-15.89-17.36-13.21
Upgrade
Net Income to Common
-25.17-29.77-29.03-15.89-17.36-13.21
Upgrade
Shares Outstanding (Basic)
222210
Upgrade
Shares Outstanding (Diluted)
222210
Upgrade
Shares Change (YoY)
16.88%3.60%6.43%172.97%45.07%57.20%
Upgrade
EPS (Basic)
-11.17-15.07-15.22-8.87-26.44-29.18
Upgrade
EPS (Diluted)
-11.17-15.07-15.22-8.87-26.44-29.18
Upgrade
Free Cash Flow
-25.75-24.23-27.71-18.97-18.15-17.25
Upgrade
Free Cash Flow Per Share
-11.42-12.26-14.53-10.59-27.65-38.12
Upgrade
EBITDA
-27.6-29.5-30.51-22.8-19.54-17.33
Upgrade
D&A For EBITDA
0.130.130.130.160.20.2
Upgrade
EBIT
-27.73-29.63-30.64-22.97-19.74-17.52
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.